Abstract #1124
Monitoring response to drug-loaded PLGA nanoparticles in a Mia PaCa-2 pancreatic tumor model with T2 and diffusion-weighted MRI
Joseph E Kobes 1 , Iman Daryaei 2 , Christine M Howison 1 , Emmaneulle J. Meuillet 3 , and Mark Pagel 4,5
1
Biomedical Engineering, University of
Arizona, Tucson, Arizona, United States,
2
Chemistry
and Biochemistry, University of Arizona, Tucson, AZ,
United States,
3
University
of Arizona Cancer Center, University of Arizona, Tucson,
Arizona, United States,
4
Dept.
of Biomedical Engineering, University of Arizona,
Tucson, Arizona, United States,
5
Dept. of
Chemistry and Biochemistry, University of Arizona,
Tucson, Arizona, United States
Poly(lactic-co-glycolic) acid nanoparticles (PLGA-NP)
can improve delivery of PHT-427, a promising
AKT-inhibitory chemotherapeutic against pancreatic
cancer. To assess the improved therapeutic effect of
PLGA-NP-loaded with PHT-427 (PLGA-PH-427), this study
employed parametric maps of the Apparent Diffusion
Coefficient (ADC) and T2 relaxation time to localized
orthotopic pancreatic tumors, and employed ADC
measurements to track tumor response to therapy,
following treatment of a MiaPaCa-2 pancreatic tumor
model with PHT-427 or PLGA-PHT-427.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
